BNTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
BioNTech SE
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 10, 2026
$89.21+1.50 (+1.71%)
Close on Oct 19, 2026
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
18.9%
47M of 251M shares
Institutional holders
282
43 new, 30 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 20 sales
Net sold $69.18M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Prof. Ugur Sahin, M.D. | 42,178,034 | 17.60% | 13G (passive) amendment | Mar 31, 2025 |
| Ugur Sahin | 40,076,320 | 15.80% | 13G (passive) amendment | Mar 31, 2026 |
| BioNTech SE | 33,333,333 | – | 13D (active) | Feb 13, 2024 |
| AT Impf GmbH | 101,702,378 | 40.20% | 13G (passive) amendment | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of BNTX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 7,571,805 | 3.01% | $704.56M | +1,862,565 | 0.03% |
| Primecap Management Co/Ca/ | 3,772,031 | 1.50% | $350.99M | −21,680 | 0.21% |
| Dodge & Cox | 3,677,591 | 1.46% | $342.20M | +800 | 0.18% |
| Flossbach Von Storch AG | 2,226,138 | 0.89% | $207.14M | −1,454,177 | 0.94% |
| T. Rowe Price Investment Management, Inc. | 2,065,456 | 0.82% | $192.19K | −3,790,617 | 0.13% |
| BlackRock, Inc. | 1,854,966 | 0.74% | $172.60M | +196,813 | 0.00% |
| Temasek Holdings (Private) Ltd | 1,506,027 | 0.60% | $140.14M | – | 0.38% |
| Bnp Paribas Arbitrage, Snc | 1,319,517 | 0.53% | $122.78M | −332,272 | 0.04% |
| Logos Global Management LP | 1,015,000 | 0.40% | $94.45M | New | 4.07% |
| GSK plc | 889,824 | 0.35% | $82.80M | – | 13.75% |
| Assenagon Asset Management S.A. | 846,526 | 0.34% | $78.77M | New | 0.05% |
| First Trust Advisors LP | 791,469 | 0.32% | $73.65M | −48,522 | 0.04% |
| Davern Capital Partners, LP | 754,550 | 0.30% | $70.21M | +449,495 | 11.97% |
| UBS Asset Management Americas Inc | 744,200 | 0.30% | $69.25M | −39,795 | 0.01% |
| Massachusetts Financial Services Co /Ma/ | 677,708 | 0.27% | $63.06M | +7,194 | 0.02% |
| Long Focus Capital Management, LLC | 624,000 | 0.25% | $58.06M | – | 1.48% |
| Baillie Gifford & Co | 592,380 | 0.24% | $55.12M | −290,192 | 0.05% |
| Goldman Sachs Group Inc | 589,903 | 0.23% | $54.89M | +493,074 | 0.00% |
| Victory Capital Management Inc | 539,787 | 0.21% | $50.23M | +62,864 | 0.03% |
| Franklin Resources Inc | 539,593 | 0.21% | $50.21M | +154,967 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 282 | 47M | 18.9% | 43 / 93 | 71 / 30 | 8M | 8M |
| Q1 2026 | 272 | 48M | 18.9% | 41 / 90 | 76 / 51 | 5M | 8M |
| Q4 2025 | 284 | 51M | 20.3% | 67 / 85 | 75 / 35 | 12M | 11M |
| Q3 2025 | 254 | 51M | 20.1% | 34 / 70 | 88 / 36 | 7M | 10M |
| Q2 2025 | 258 | 54M | 21.4% | 33 / 85 | 82 / 51 | 8M | 6M |
| Q1 2025 | 279 | 52M | 20.6% | 39 / 76 | 100 / 58 | 5M | 4M |
| Q4 2024 | 303 | 51M | 20.2% | 63 / 84 | 88 / 49 | 11M | 4M |
| Q3 2024 | 297 | 44M | 17.6% | 77 / 73 | 96 / 64 | 14M | 8M |
| Q2 2024 | 286 | 41M | 16.4% | 37 / 87 | 99 / 36 | 6M | 8M |
| Q1 2024 | 287 | 43M | 17.2% | 50 / 97 | 88 / 43 | 6M | 4M |
| Q4 2023 | 282 | 41M | 16.5% | 70 / 92 | 70 / 38 | 7M | 3M |
| Q3 2023 | 252 | 37M | 14.7% | 33 / 72 | 76 / 31 | 4M | 4M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of BNTX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Contrafund | 3,278,252 | 1.31% | $305.04M | 0.17% | Jun 30, 2026 |
| Dodge & Cox International Stock Fund | 2,517,713 | 1.00% | $234.27M | 0.35% | Jun 30, 2026 |
| Vanguard Capital Opportunity Fund | 2,189,120 | 0.87% | $203.70M | 0.62% | Jun 30, 2026 |
| T. Rowe Price Mid-Cap Growth Fund, Inc. | 1,018,613 | 0.41% | $94.78M | 0.41% | Jun 30, 2026 |
| PRIMECAP Odyssey Aggressive Growth Fund | 897,156 | 0.36% | $81.26M | 1.10% | Jul 31, 2026 |
| First Trust NYSE Arca Biotechnology Index Fund | 794,727 | 0.32% | $73.95M | 2.63% | Jun 30, 2026 |
| Fidelity Contrafund K6 | 704,487 | 0.28% | $65.55M | 0.17% | Jun 30, 2026 |
| Fidelity Emerging Markets Fund | 660,800 | 0.26% | $59.86M | 0.55% | Jul 31, 2026 |
| iShares Biotechnology ETF | 647,133 | 0.26% | $60.22M | 0.66% | Jun 30, 2026 |
| Dodge & Cox Global Stock Fund | 525,778 | 0.21% | $48.92M | 0.38% | Jun 30, 2026 |
| MFS Mid Cap Value Fund | 487,157 | 0.19% | $45.33M | 0.26% | Jun 30, 2026 |
| PRIMECAP Odyssey Growth Fund | 354,600 | 0.14% | $32.12M | 0.53% | Jul 31, 2026 |
| Strategic Advisers Fidelity Emerging Markets Fund | 244,800 | 0.10% | $23.49M | 0.06% | May 31, 2026 |
| Fidelity Value Fund | 200,000 | 0.08% | $18.12M | 0.17% | Jul 31, 2026 |
| Schwab Fundamental International Equity ETF | 196,561 | 0.08% | $18.86M | 0.08% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Ugur Sahin | Chief Executive Officer, 10% owner | 39,432,320 | 15.70% | Sep 30, 2026 |
| Annemarie Hanekamp | Chief Commercial Officer | – | – | May 13, 2026 |
| James Timothy Patrick Ryan | See remarks. | 4,795 | 0.00% | May 13, 2026 |
| Kylie Jimenez | Chief People Officer | – | – | May 13, 2026 |
| Gomez Ramon Zapata | Chief Financial Officer | – | – | May 13, 2026 |
| Sierk Poetting | Chief Operating Officer | 540,901 | 0.22% | May 13, 2026 |
| Ozlem Tureci | Chief Medical Officer | – | – | Mar 18, 2026 |
| Iris Katharina Low-Friedrich | Director | – | – | Jun 26, 2026 |
| Susanne Schaffert | Director | – | – | Jun 26, 2026 |
| Nicola Claire Blackwood | Director | – | – | Mar 25, 2026 |
| Anja Morawietz | Director | 240 | 0.00% | Mar 25, 2026 |
| Rudolf Staudigl | Director | 400 | 0.00% | Mar 25, 2026 |
| Helmut Wolfgang Jeggle | Director | 989,267 | 0.39% | Mar 18, 2026 |
| Michael Motschmann | Director | – | – | Mar 18, 2026 |
| Ulrich Wandschneider | Director | 1,927 | 0.00% | Mar 18, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Ugur Sahin Chief Executive Officer, 10% owner | Sep 30, 2026 | Sale(10b5-1 plan) | −32,000 | $98.12 | $3.14M | 214,209 |
| Ugur Sahin Chief Executive Officer, 10% owner | Sep 29, 2026 | Sale(10b5-1 plan) | −34,000 | $98.26 | $3.34M | 246,209 |
| Ugur Sahin Chief Executive Officer, 10% owner | Sep 28, 2026 | Sale(10b5-1 plan) | −34,000 | $98.47 | $3.35M | 280,209 |
| Ugur Sahin Chief Executive Officer, 10% owner | Sep 25, 2026 | Sale(10b5-1 plan) | −27,000 | $98.69 | $2.66M | 314,209 |
| Ugur Sahin Chief Executive Officer, 10% owner | Sep 24, 2026 | Sale(10b5-1 plan) | −39,000 | $98.99 | $3.86M | 341,209 |
| Ugur Sahin Chief Executive Officer, 10% owner | Sep 23, 2026 | Sale(10b5-1 plan) | −30,000 | $99.40 | $2.98M | 380,209 |
| Ugur Sahin Chief Executive Officer, 10% owner | Sep 22, 2026 | Sale(10b5-1 plan) | −46,000 | $100.72 | $4.63M | 410,209 |
| Ugur Sahin Chief Executive Officer, 10% owner | Sep 21, 2026 | Sale(10b5-1 plan) | −33,000 | $97.81 | $3.23M | 456,209 |
| Ugur Sahin Chief Executive Officer, 10% owner | Sep 18, 2026 | Sale(10b5-1 plan) | −30,000 | $96.22 | $2.89M | 489,209 |
| Ugur Sahin Chief Executive Officer, 10% owner | Sep 17, 2026 | Sale(10b5-1 plan) | −34,000 | $98.60 | $3.35M | 519,209 |
| Ugur Sahin Chief Executive Officer, 10% owner | Sep 16, 2026 | Sale(10b5-1 plan) | −15,000 | $96.09 | $1.44M | 553,209 |
| Ugur Sahin Chief Executive Officer, 10% owner | Sep 15, 2026 | Sale(10b5-1 plan) | −34,000 | $96.49 | $3.28M | 568,209 |
| Ugur Sahin Chief Executive Officer, 10% owner | Sep 14, 2026 | Sale(10b5-1 plan) | −41,000 | $99.45 | $4.08M | 602,209 |
| Ugur Sahin Chief Executive Officer, 10% owner | Sep 11, 2026 | Sale(10b5-1 plan) | −45,000 | $96.93 | $4.36M | 643,209 |
| Ugur Sahin Chief Executive Officer, 10% owner | Sep 10, 2026 | Sale(10b5-1 plan) | −20,500 | $96.31 | $1.97M | 688,209 |
| Ugur Sahin Chief Executive Officer, 10% owner | Sep 9, 2026 | Sale(10b5-1 plan) | −36,000 | $97.78 | $3.52M | 708,709 |
| Ugur Sahin Chief Executive Officer, 10% owner | Sep 8, 2026 | Sale(10b5-1 plan) | −37,000 | $99.20 | $3.67M | 744,709 |
| Ugur Sahin Chief Executive Officer, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −31,500 | $103.52 | $3.26M | 781,709 |
| Ugur Sahin Chief Executive Officer, 10% owner | Sep 3, 2026 | Sale(10b5-1 plan) | −45,000 | $102.85 | $4.63M | 813,209 |
| Sierk Poetting Chief Operating Officer | Apr 22, 2026 | Sale(10b5-1 plan) | −50,000 | $110.56 | $5.53M | 399,387 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| GmbH Medine Officer, 10% Stockholder | Sep 3, 2026 | 858,209 | $89.09M | Sep 3, 2026 | Stock Option Exercise |
| GmbH Medine Officer, 10% Stockholder | May 12, 2026 | 858,209 | $80.38M | May 13, 2026 | Stock Option Exercise |
| Sierk Poetting Officer | Mar 11, 2026 | 150,000 | $12.58M | Mar 11, 2026 | Stock Option Exercise |
| GmbH Medine Officer, 10% Stockholder | Feb 12, 2026 | 858,209 | $93.87M | Feb 12, 2026 | Stock Option Exercise |
| Ozlem Tureci Officer | Nov 28, 2025 | 123,331 | $12.67M | Nov 28, 2025 | Stock Option Exercise |
| GmbH Medine Officer, 10% Stockholder | Nov 13, 2025 | 1,114,130 | $124.45M | Nov 13, 2025 | Stock Option Exercise |
| Helmut Wolfgang Jeggle Director | Nov 5, 2025 | 150,000 | $15.51M | Nov 5, 2025 | Private placement |
| Kg Athos 10% Stockholder | Sep 5, 2025 | 500,000 | $56.23M | Sep 5, 2025 | Private placement |
| Ozlem Tureci Officer | Aug 15, 2025 | 185,001 | $20.85M | Aug 15, 2025 | Stock Option Exercise |
| GmbH Medine Officer, 10% Stockholder | Aug 15, 2025 | 1,774,837 | $200.02M | Aug 15, 2025 | Stock Option Exercise |
| Kg Athos 10% Stockholder | Jun 4, 2025 | 325,000 | $36.76M | May 28, 2025 | Private placement |
| Helmut Wolfgang Jeggle Director | Jun 4, 2025 | 150,000 | $16.97M | Jun 4, 2025 | Private placement |
| Kg Athos 10% Stockholder | Jun 2, 2025 | 175,000 | $19.39M | Jun 2, 2025 | Private placement |
| Kg Athos 10% Stockholder | May 28, 2025 | 500,000 | $49.34M | May 28, 2025 | Private placement |
| Helmut Wolfgang Jeggle Director | May 7, 2025 | 150,000 | $14.21M | May 7, 2025 | Private placement |